KANAPH Therapeutics Inc (Ticker: 0082N0 KS) is a South Korean biotechnology company specializing in human genome analysis and the development of targeted therapies. KANAPH Therapeutics plans to list on the KOSDAQ exchange on March 16, 2026, planning to offer 2.00 million shares at a price of KRW 20,000. This will raise an offer size of KRW 40.00 billion (approximately USD 27.68 million). The IPO implies a market capitalization of USD 179.45 million at the offer price.

According to sources, the offering consists of 100% primary shares, indicating that the IPO proceeds will be directed entirely to the company to support its ongoing operations and clinical development programs. The company focuses on next-generation treatments based on bioinformatics platforms, including bispecific antibodies, synthetic drugs, and ADCs. Its clinical pipeline reportedly features KNP-101, a first-in-class FAP-targeted interleukin-12 (IL-12) candidate designed to treat solid tumors—such as non-small cell lung cancer and colorectal cancer—by addressing the immunosuppressive tumor microenvironment.

Capital Tankers Corp. (Ticker: CAPT NO) is a company specializing in the operation of an expanding oil tanker fleet. Formed as a spin-off from parent company Capital Maritime & Trading, Capital Tankers Corp. plans to list on the Euronext Growth Oslo exchange on March 17, 2026. The company is offering shares at a price of NKr 134 each, reportedly raising an upsized total of $500 million, including the overallotment option, following strong investor demand. This gives the company an implied valuation of $1.4 billion.

Post-IPO, Capital Maritime & Trading will retain a 73.7% controlling stake in the business, while public investors will hold the remaining 26.3%. According to sources, the company's fleet currently includes 3 operational vessels, with 5 slated for delivery in the first quarter of 2026 and another 22 under construction. In 2025, the unit generated a reported profit of $15.3 million on $42.2 million in revenue. The offering is being supported by Fearnley Securities and Pareto Securities acting as joint coordinators, alongside Clarksons Securities and SB1 Markets serving as bookrunners.

ARENIT Industrie SE (Ticker: ARENISDB SS) is a German company operating as an industrial group that applies the Nordic compounder model to small and medium-sized industrial businesses in the DACH region. ARENIT plans to list Swedish Depository Receipts on the FN Stockholm exchange on March 17, 2026. The company is planning to offer 6.49 million receipts at a price of SEK 77.00 each, raising a base offer size of SEK 500.00 million (approximately USD 55.09 million). If the over-allotment option is fully exercised, the total offering size could reach SEK 575.00 million (USD 63.36 million).

According to sources, ARENIT intends to use the net proceeds to finance future acquisitions aimed at accelerating the Group's growth. Reportedly, the offering consists of both primary shares and secondary shares sold by existing shareholders, including the company's co-founders. Pareto Securities AB is acting as the manager for the IPO, and cornerstone investors have reportedly committed to acquiring roughly 64 percent of the base offering.

IMBiologics (Ticker: 493280 KS) is a South Korean company specializing in the research and development of innovative antibody drugs for autoimmune diseases and immuno-oncology. IMBiologics plans to list on the KOSDAQ on March 20, 2026, planning to offer 2,000,000 shares at a price of 26,000 KRW, raising 52.0 billion KRW ($35.09 million USD). Based on the total post-IPO shares, the company has an estimated market valuation of approximately 384.5 billion KRW ($259.49 million USD).

The underwriters for the offering are Korea Investment & Securities and Shinhan Investment & Securities. According to sources, the IPO saw strong demand, achieving an institutional competition ratio of 839.23 to 1. Additional facts indicate that the company operates a full-cycle drug development system and has previously secured significant technology transfer agreements for its lead pipeline assets, IMB-101 and IMB-102. Reportedly, the offering consists entirely of primary shares, with a 75 percent allocation to institutional investors and 25 percent to the general public.

Delton Technology Guangzhou Inc (Ticker: 1989 HK) is a Chinese company specializing in the development, manufacture, and sale of customized printed circuit boards (PCBs) for high-performance servers and other computing applications. Delton Technology plans to list on the Hong Kong Stock Exchange on March 20, 2026, planning to offer 46.00 million shares at a price of HKD 71.88, raising HKD 3.31 billion and a total offer size of USD 422.44 million.

Delton Technology plans to use the IPO proceeds for R&D and product capacity, brand promotion and business development, working capital, and strategic acquisitions. Reportedly, the company ranks third globally among high-performance server PCB manufacturers and first among those headquartered in the Chinese Mainland. Structured as an H Share company, its underwriters according to sources include CITIC Securities, GF Securities, Guolian Securities, HSBC, and Huatai Financial. Additional facts indicate the company's computing application PCBs, particularly for AI and general-purpose servers, accounted for nearly 74% of total revenue by late 2025, driven by expanding datacenters and robotics.

Vincorion SE (Ticker: VINC GR) is a German company specializing in power and mechatronic solutions for defense platforms and advanced aviation systems. Vincorion plans to list on the Frankfurt Stock Exchange on March 20, 2026, offering up to 20,297,500 shares at a fixed price of €17.00 per share, raising up to €345 million (approximately $397 million). The offer price implies a total market capitalization of €850 million (approximately $978 million).

The IPO is structured as an all-secondary offering. Vincorion is currently backed by private equity firm Star Capital, which will reportedly receive all proceeds from the sale and be subject to a 180-day lock-up period. According to sources, the order-taking process is operating on an accelerated three-day timeline to minimize exposure to sudden market volatility. Furthermore, cornerstone investors including Fidelity International, Invesco, and T. Rowe Price have reportedly pre-committed an aggregate amount of €105 million in guaranteed allocations. The offering is being supported by a banking syndicate with Berenberg, BNP Paribas, and J.P. Morgan serving as joint global coordinators, alongside Commerzbank and UniCredit.